Behind Riabni® A Robust Biosimilars Program

RIABNI® IS A PROVEN BIOSIMILAR TO RITUXAN®

Based on a comprehensive totality of evidence, RIABNI® demonstrates biosimilarity to Rituxan® with no clinically meaningful differences in safety and efficacy.1

Table name here
BIOSIMILAR DEVELOPMENT STEPS FDA requirements for biosimilar approval2 RIABNI® 1,3,4
Analytical comparison
Nonclinical studies
Clinical pharmacology
Comparative clinical study(homogeneous low-grade FL population)
  • FL = follicular lymphoma.

RIABNI® is FDA approved for all Rituxan® oncology indications4,5

I was actually very excited [about Amgen Biosimilars] because Amgen has a very long experience in manufacturing biologics.

– Dr Lee Schwartzberg, Oncologist

RIABNI® efficacy proven similar to Rituxan® with no clinically meaningful differences

JASMINE: Randomized, double-blind international study that demonstrated clinical similarity of RIABNI® to Rituxan® (6 infusions of 375 mg/m2 at weeks 1-4, 12, 20) in patients* with CD20-positive previously-untreated follicular lymphoma (FL).1,3,6

OVERALL RESPONSE RATE (ORR) RIABNI® VS RITUXAN® (primary endpoint)1,3

Overall response rate of RIABNI<sup>®</sup> vs. Rituxan<sup>®</sup>
Overall response rate of RIABNI<sup>®</sup> vs. Rituxan<sup>®</sup>
  • ORR = complete response + unconfirmed complete response + partial response.
  • Secondary endpoints: RD of ORR at week 12, percentage of patients with complete depletion of CD19 cell count and total levels of IgE and IgM (baseline to day 8), immunogenicity of RIABNI® vs Rituxan®, progression-free survival (PFS) and overall survival (OS).1,3,6

At the end of the study, all patients were alive and median PFS was not reached (both treatment arms)3

  • *Patients (N = 250) with confirmed B-cell FL grade 1, 2, or 3a; low tumor burden, ≥ 18 years of age were enrolled from 150 sites in Europe, North America, Latin America, and Asia Pacific.1,3

  • †Central review.

    CI = confidence interval; IgE = Immunoglobulin E; IgM = Immunoglobulin M.

RIABNI® has a benefit/risk profile that is consistent with Rituxan® with no clinically meaningful differences in treatment-emergent adverse events (TEAEs) and serious adverse events (AEs).1

Table name here
  RIABNI®
(N = 128)
n (%)		 Rituxan®
(N = 126)
n (%)
Most common TEAEs (≥ 5%)    
Abdominal pain 4 (3.1) 10 (7.9)
Asthenia 12 (9.4) 6 (4.8)
Diarrhea 3 (2.3) 9 (7.1)
Fatigue 13 (10.2) 12 (9.5)
Headache 15 (11.7) 12 (9.5)
Nausea 6 (4.7) 14 (11.1)
Pruritus 6 (4.7) 12 (9.5)
Pyrexia 8 (6.3) 8 (6.3)
Rash 9 (7.0) 6 (4.8)
Throat irritation 9 (7.0) 8 (6.3)
Upper respiratory tract infection 7 (5.5) 1 (0.8)
Urticaria 7 (5.5) 2 (1.6)
Grade ≥ 3 AE 14 (10.9) 13 (10.3)
Any events of interestAny AE of interest 63 (49.2) 57 (45.2)
Infusion reactions including hypersensitivity* 55 (43.0) 54 (42.9)
Hematological reactions 7 (5.5) 6 (4.8)
Cardiac disorders 3 (2.3) 2 (1.6)
Serious infections 2 (1.6) 0 (0.0)
Severe mucocutaneous reactions 1 (0.8) 0 (0.0)
  • No patients experienced gastrointestinal perforation, hepatitis B reactivation, opportunistic infection, progressive multifocal leukoencephalopathy, reversible posterior leukoencephalopathy syndrome, or tumor lysis syndrome.
  • *Infusion reactions including hypersensitivity adverse events of interest must have start date the same as, or 1 day after, an intraperitoneal product administration start date.

The incidence of developing anti-drug antibodies (ADAs) was consistent across the treatment groups (< 2.5% in either group) and the majority were transient1

<p>See how RIABNI® and Rituxan® have identical dosing and administration</p>
×
Amgen stands with our local Los Angeles community. Click here to learn what we are doing to support and contact us if the fires have impacted your access to Amgen medication.